$ABIO Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ARCA biopharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ARCA biopharma, Inc.. Get notifications about new insider transactions in ARCA biopharma, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 14 2012 | ABIO | ARCA biopharma, In ... | ZABRISKIE JOHN L | Director | Option Exercise | A | 1.00 | 3,500 | 3,500 | 3,500 | |
| May 24 2011 | ABIO | ARCA biopharma, In ... | Wheeler Patrick M | Chief Financial Off ... | Option Exercise | A | 2.24 | 20,000 | 44,800 | 20,000 | |
| May 24 2011 | ABIO | ARCA biopharma, In ... | Ozeroff Christopher David | SVP and General Cou ... | Option Exercise | A | 2.24 | 20,000 | 44,800 | 20,000 | |
| May 24 2011 | ABIO | ARCA biopharma, In ... | BRISTOW MICHAEL R | President and CEO | Option Exercise | A | 2.24 | 30,000 | 67,200 | 30,000 | |
| Jul 07 2010 | ABIO | ARCA biopharma, In ... | Ozeroff Christopher David | SVP & GENERAL COUNS ... | Option Exercise | M | 0.06 | 4,101 | 246 | 0 | |
| Jul 07 2010 | ABIO | ARCA biopharma, In ... | Ozeroff Christopher David | SVP & GENERAL COUNS ... | Sell | J | 0.00 | 2,051 | 0 | 41,758 | 43.8 K to 41.8 K (-4.68 %) |
| Jul 07 2010 | ABIO | ARCA biopharma, In ... | Ozeroff Christopher David | SVP & GENERAL COUNS ... | Buy | M | 0.06 | 4,101 | 246 | 43,809 | 39.7 K to 43.8 K (+10.33 %) |
| May 28 2010 | ABIO | ARCA biopharma, In ... | Ozeroff Christopher David | SVP & GENERAL COUNS ... | Sell | J | 0.00 | 39,709 | 0 | 39,708 | 79.4 K to 39.7 K (-50.00 %) |
| Mar 31 2010 | ABIO | ARCA biopharma, In ... | Atlas Venture Fund VII L P | 10% Owner | Sell | S | 7.56 | 140,000 | 1,058,400 | 1,337,612 | 1.5 M to 1.3 M (-9.47 %) |
| Mar 31 2010 | ABIO | ARCA biopharma, In ... | FORMELA JEAN FRANCOIS | Director | Sell | S | 7.56 | 140,000 | 1,058,400 | 1,337,612 | 1.5 M to 1.3 M (-9.47 %) |
| Mar 30 2010 | ABIO | ARCA biopharma, In ... | Grais Linda S | Director | Sell | S | 7.30 | 187,209 | 1,366,626 | 491,889 | 679.1 K to 491.9 K (-27.57 %) |
| Mar 30 2010 | ABIO | ARCA biopharma, In ... | Grais Linda S | Director | Sell | S | 7.98 | 23,600 | 188,328 | 679,098 | 702.7 K to 679.1 K (-3.36 %) |
| Feb 22 2010 | ABIO | ARCA biopharma, In ... | BRISTOW MICHAEL R | President and CEO | Option Exercise | A | 2.97 | 16,000 | 47,520 | 16,000 | |
| Feb 22 2010 | ABIO | ARCA biopharma, In ... | Wheeler Patrick M | acting Chief Financ ... | Option Exercise | A | 2.97 | 6,400 | 19,008 | 6,400 | |
| Feb 22 2010 | ABIO | ARCA biopharma, In ... | Ozeroff Christopher David | SVP & GENERAL COUNS ... | Option Exercise | A | 2.97 | 6,400 | 19,008 | 6,400 | |
| Feb 09 2010 | ABIO | ARCA biopharma, In ... | SOBEL BURTON E | Director | Option Exercise | A | 2.73 | 3,500 | 9,555 | 3,500 | |
| Feb 09 2010 | ABIO | ARCA biopharma, In ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | A | 2.73 | 3,500 | 9,555 | 3,500 | |
| Feb 09 2010 | ABIO | ARCA biopharma, In ... | ZABRISKIE JOHN L | Director | Option Exercise | A | 2.73 | 3,500 | 9,555 | 3,500 | |
| Feb 09 2010 | ABIO | ARCA biopharma, In ... | Grais Linda S | Director | Option Exercise | A | 2.73 | 3,500 | 9,555 | 3,500 | |
| Feb 09 2010 | ABIO | ARCA biopharma, In ... | PENDERGAST MARY K | Director | Option Exercise | A | 2.73 | 3,500 | 9,555 | 3,500 | |
| Feb 09 2010 | ABIO | ARCA biopharma, In ... | BREWER RICHARD B | Director | Option Exercise | A | 2.73 | 3,500 | 9,555 | 3,500 | |
| Feb 09 2010 | ABIO | ARCA biopharma, In ... | LOVE TED W | Director | Option Exercise | A | 2.73 | 3,500 | 9,555 | 3,500 | |
| Feb 09 2010 | ABIO | ARCA biopharma, In ... | FREYTAG J WILLIAM | Director | Option Exercise | A | 2.73 | 3,500 | 9,555 | 3,500 | |
| Oct 15 2009 | ABIO | ARCA biopharma, In ... | BRISTOW MICHAEL R | President and CEO | Option Exercise | M | 0.06 | 7,394 | 444 | 0 | |
| Oct 15 2009 | ABIO | ARCA biopharma, In ... | BRISTOW MICHAEL R | President and CEO | Buy | M | 0.06 | 7,394 | 444 | 280,071 | 272.7 K to 280.1 K (+2.71 %) |
| Jul 22 2009 | ABIO | ARCA biopharma, In ... | Lowe David George | Director | Sell | S | 3.94 | 78,800 | 310,370 | 129,600 | 208.4 K to 129.6 K (-37.81 %) |
| Jul 22 2009 | ABIO | ARCA biopharma, In ... | Lowe David George | Director | Sell | S | 4.44 | 102,000 | 452,574 | 208,400 | 310.4 K to 208.4 K (-32.86 %) |
| Jul 22 2009 | ABIO | ARCA biopharma, In ... | Lowe David George | Director | Sell | S | 4.19 | 25,000 | 104,790 | 310,400 | 335.4 K to 310.4 K (-7.45 %) |
| Jun 26 2009 | ABIO | ARCA biopharma, In ... | FALBERG KATHRYN E | CFO and COO | Option Exercise | A | 2.90 | 50,000 | 145,000 | 50,000 | |
| Jun 17 2009 | ABIO | ARCA biopharma, In ... | FALBERG KATHRYN E | CFO and COO | Sell | S | 3.68 | 500 | 1,840 | 0 | 500 to 0 (-100.00 %) |
| Jun 17 2009 | ABIO | ARCA biopharma, In ... | FALBERG KATHRYN E | CFO and COO | Sell | S | 3.67 | 1,300 | 4,771 | 500 | 1.8 K to 500 (-72.22 %) |
| Jun 17 2009 | ABIO | ARCA biopharma, In ... | FALBERG KATHRYN E | CFO and COO | Sell | S | 3.66 | 1,400 | 5,124 | 1,800 | 3.2 K to 1.8 K (-43.75 %) |
| Jun 17 2009 | ABIO | ARCA biopharma, In ... | FALBERG KATHRYN E | CFO and COO | Sell | S | 3.65 | 500 | 1,825 | 3,200 | 3.7 K to 3.2 K (-13.51 %) |
| Jun 17 2009 | ABIO | ARCA biopharma, In ... | FALBERG KATHRYN E | CFO and COO | Sell | S | 3.64 | 200 | 728 | 3,700 | 3.9 K to 3.7 K (-5.13 %) |
| Jun 17 2009 | ABIO | ARCA biopharma, In ... | FALBERG KATHRYN E | CFO and COO | Sell | S | 3.62 | 1,600 | 5,792 | 3,900 | 5.5 K to 3.9 K (-29.09 %) |
| Jun 17 2009 | ABIO | ARCA biopharma, In ... | FALBERG KATHRYN E | CFO and COO | Sell | S | 3.62 | 500 | 1,808 | 5,500 | 6 K to 5.5 K (-8.33 %) |
| Jun 17 2009 | ABIO | ARCA biopharma, In ... | FALBERG KATHRYN E | CFO and COO | Sell | S | 3.61 | 6,700 | 24,187 | 6,000 | 12.7 K to 6 K (-52.76 %) |
| Jun 17 2009 | ABIO | ARCA biopharma, In ... | FALBERG KATHRYN E | CFO and COO | Sell | S | 3.60 | 100 | 360 | 12,700 | 12.8 K to 12.7 K (-0.78 %) |
| Jun 17 2009 | ABIO | ARCA biopharma, In ... | FALBERG KATHRYN E | CFO and COO | Sell | S | 3.59 | 6,000 | 21,540 | 12,800 | 18.8 K to 12.8 K (-31.91 %) |
| Jun 17 2009 | ABIO | ARCA biopharma, In ... | FALBERG KATHRYN E | CFO and COO | Sell | S | 3.58 | 2,200 | 7,876 | 18,800 | 21 K to 18.8 K (-10.48 %) |
| Jun 15 2009 | ABIO | ARCA biopharma, In ... | Lowe David George | Director | Sell | S | 3.90 | 6,100 | 23,818 | 335,400 | 341.5 K to 335.4 K (-1.79 %) |
| Jun 15 2009 | ABIO | ARCA biopharma, In ... | Lowe David George | Director | Sell | S | 3.94 | 3,800 | 14,990 | 341,500 | 345.3 K to 341.5 K (-1.10 %) |
| Jun 15 2009 | ABIO | ARCA biopharma, In ... | Lowe David George | Director | Sell | S | 3.84 | 40,700 | 156,479 | 345,300 | 386 K to 345.3 K (-10.54 %) |
| Jun 15 2009 | ABIO | ARCA biopharma, In ... | Skyline Venture Partners Quali ... | Sell | S | 3.90 | 6,100 | 23,818 | 335,400 | 341.5 K to 335.4 K (-1.79 %) | |
| Jun 15 2009 | ABIO | ARCA biopharma, In ... | Skyline Venture Partners Quali ... | Sell | S | 3.94 | 3,800 | 14,990 | 341,500 | 345.3 K to 341.5 K (-1.10 %) | |
| Jun 15 2009 | ABIO | ARCA biopharma, In ... | Skyline Venture Partners Quali ... | Sell | S | 3.84 | 40,700 | 156,479 | 345,300 | 386 K to 345.3 K (-10.54 %) | |
| Jun 10 2009 | ABIO | ARCA biopharma, In ... | Skyline Venture Partners Quali ... | Sell | S | 3.96 | 36,000 | 142,448 | 386,000 | 422 K to 386 K (-8.53 %) | |
| Jun 10 2009 | ABIO | ARCA biopharma, In ... | Skyline Venture Partners Quali ... | Sell | S | 3.99 | 47,500 | 189,392 | 422,000 | 469.5 K to 422 K (-10.12 %) | |
| Jun 10 2009 | ABIO | ARCA biopharma, In ... | Skyline Venture Partners Quali ... | Sell | S | 4.21 | 65,708 | 276,388 | 469,500 | 535.2 K to 469.5 K (-12.28 %) | |
| Jun 10 2009 | ABIO | ARCA biopharma, In ... | Lowe David George | Director | Sell | S | 3.96 | 36,000 | 142,448 | 386,000 | 422 K to 386 K (-8.53 %) |
| Jun 10 2009 | ABIO | ARCA biopharma, In ... | Lowe David George | Director | Sell | S | 3.99 | 47,500 | 189,392 | 422,000 | 469.5 K to 422 K (-10.12 %) |
| Jun 10 2009 | ABIO | ARCA biopharma, In ... | Lowe David George | Director | Sell | S | 4.21 | 65,708 | 276,388 | 469,500 | 535.2 K to 469.5 K (-12.28 %) |
| Jun 03 2009 | ABIO | ARCA biopharma, In ... | Skyline Venture Partners Quali ... | 10% Owner | Sell | J | 0.00 | 342,375 | 0 | 535,208 | 877.6 K to 535.2 K (-39.01 %) |
| Jun 03 2009 | ABIO | ARCA biopharma, In ... | Lowe David George | Director | Sell | J | 0.00 | 342,375 | 0 | 535,208 | 877.6 K to 535.2 K (-39.01 %) |
| Apr 08 2009 | ABIO | ARCA biopharma, In ... | BOULDER VENTURES IV ANNEX LP | 10% Owner | Buy | J | 0.00 | 31 | 0 | 549 | 518 to 549 (+5.98 %) |
| Apr 08 2009 | ABIO | ARCA biopharma, In ... | BOULDER VENTURES IV ANNEX LP | 10% Owner | Buy | J | 0.00 | 518 | 0 | 518 | 0 to 518 |
| Apr 08 2009 | ABIO | ARCA biopharma, In ... | BOULDER VENTURES IV ANNEX LP | 10% Owner | Sell | J | 0.00 | 3,292 | 0 | 44,715 | 48 K to 44.7 K (-6.86 %) |
| Apr 08 2009 | ABIO | ARCA biopharma, In ... | BOULDER VENTURES IV ANNEX LP | 10% Owner | Sell | J | 0.00 | 49,708 | 0 | 675,403 | 725.1 K to 675.4 K (-6.86 %) |
| Mar 03 2009 | ABIO | ARCA biopharma, In ... | LOVE TED W | Director | Option Exercise | A | 5.29 | 7,500 | 39,675 | 7,500 | |
| Mar 03 2009 | ABIO | ARCA biopharma, In ... | Grais Linda S | Director | Option Exercise | A | 5.29 | 7,500 | 39,675 | 7,500 | |
| Mar 03 2009 | ABIO | ARCA biopharma, In ... | Lowe David George | Director | Option Exercise | A | 5.29 | 7,500 | 39,675 | 7,500 | |
| Mar 03 2009 | ABIO | ARCA biopharma, In ... | ZABRISKIE JOHN L | Director | Option Exercise | A | 5.29 | 7,500 | 39,675 | 7,500 | |
| Mar 03 2009 | ABIO | ARCA biopharma, In ... | SOBEL BURTON E | Director | Option Exercise | A | 5.29 | 7,500 | 39,675 | 7,500 | |
| Mar 03 2009 | ABIO | ARCA biopharma, In ... | PENDERGAST MARY K | Director | Option Exercise | A | 5.29 | 7,500 | 39,675 | 7,500 | |
| Mar 03 2009 | ABIO | ARCA biopharma, In ... | FREYTAG J WILLIAM | Director | Option Exercise | A | 5.29 | 7,500 | 39,675 | 7,500 | |
| Mar 03 2009 | ABIO | ARCA biopharma, In ... | FORMELA JEAN FRANCOIS | Director | Option Exercise | A | 5.29 | 7,500 | 39,675 | 7,500 | |
| Mar 03 2009 | ABIO | ARCA biopharma, In ... | FALBERG KATHRYN E | CFO and COO | Option Exercise | A | 5.29 | 49,500 | 261,855 | 49,500 | |
| Jun 05 2008 | ABIO | ARCA biopharma, In ... | SOBEL BURTON E | Director | Option Exercise | A | 0.73 | 15,000 | 10,950 | 15,000 | |
| Jun 05 2008 | ABIO | ARCA biopharma, In ... | Popovits Kimberly J | Director | Option Exercise | A | 0.73 | 20,000 | 14,600 | 20,000 | |
| Jun 05 2008 | ABIO | ARCA biopharma, In ... | PERRY MARK L | Director | Option Exercise | A | 0.73 | 15,000 | 10,950 | 15,000 | |
| Jun 05 2008 | ABIO | ARCA biopharma, In ... | PENDERGAST MARY K | Director | Option Exercise | A | 0.73 | 15,000 | 10,950 | 15,000 | |
| Jun 04 2008 | ABIO | ARCA biopharma, In ... | GAVIN JAMES R III | Director | Option Exercise | A | 0.73 | 15,000 | 10,950 | 15,000 | |
| Mar 25 2008 | ABIO | ARCA biopharma, In ... | LOVE TED W | C.E.O | Buy | P | 0.67 | 29,000 | 19,479 | 57,289 | 28.3 K to 57.3 K (+102.51 %) |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | LEVY MICHAEL D | Executive Vice Pres ... | Option Exercise | A | 1.57 | 29,167 | 45,646 | 29,167 | |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | LEVY MICHAEL D | Executive Vice Pres ... | Option Exercise | A | 1.57 | 70,833 | 110,854 | 70,833 | |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | LEVY MICHAEL D | Executive Vice Pres ... | Buy | I | 1.85 | 3,605 | 6,680 | 20,821 | 17.2 K to 20.8 K (+20.94 %) |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | LEVY MICHAEL D | Executive Vice Pres ... | Buy | I | 2.90 | 3,536 | 10,249 | 17,216 | 13.7 K to 17.2 K (+25.85 %) |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | LOVE TED W | C.E.O. | Option Exercise | A | 1.57 | 58,333 | 91,291 | 58,333 | |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | LOVE TED W | C.E.O. | Option Exercise | A | 1.57 | 141,667 | 221,709 | 141,667 | |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | LOVE TED W | C.E.O. | Buy | I | 1.85 | 1,598 | 2,961 | 28,289 | 26.7 K to 28.3 K (+5.99 %) |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | LOVE TED W | C.E.O. | Buy | I | 2.90 | 5,649 | 16,374 | 26,691 | 21 K to 26.7 K (+26.85 %) |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr. VP CFO and Gene ... | Option Exercise | A | 1.57 | 29,168 | 45,648 | 29,168 | |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr. VP CFO and Gene ... | Option Exercise | A | 1.57 | 70,832 | 110,852 | 70,832 | |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr. VP CFO and Gene ... | Buy | I | 1.48 | 1,932 | 2,857 | 6,511 | 4.6 K to 6.5 K (+42.19 %) |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr. VP CFO and Gene ... | Buy | I | 1.85 | 1,445 | 2,678 | 4,579 | 3.1 K to 4.6 K (+46.11 %) |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr. VP CFO and Gene ... | Buy | I | 2.90 | 924 | 2,678 | 3,134 | 2.2 K to 3.1 K (+41.81 %) |
| Feb 04 2008 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr. VP CFO and Gene ... | Buy | I | 2.79 | 962 | 2,682 | 2,210 | 1.2 K to 2.2 K (+77.08 %) |
| Jun 01 2007 | ABIO | ARCA biopharma, In ... | ZUBROW BARRY L | Director | Option Exercise | A | 3.67 | 20,000 | 73,400 | 20,000 | |
| Jun 01 2007 | ABIO | ARCA biopharma, In ... | SOBEL BURTON E | Director | Option Exercise | A | 3.67 | 15,000 | 55,050 | 15,000 | |
| Jun 01 2007 | ABIO | ARCA biopharma, In ... | Popovits Kimberly J | Director | Option Exercise | A | 3.67 | 15,000 | 55,050 | 15,000 | |
| Jun 01 2007 | ABIO | ARCA biopharma, In ... | PERRY MARK L | Director | Option Exercise | A | 3.67 | 15,000 | 55,050 | 15,000 | |
| Jun 01 2007 | ABIO | ARCA biopharma, In ... | PENDERGAST MARY K | Director | Option Exercise | A | 3.67 | 15,000 | 55,050 | 15,000 | |
| Jun 01 2007 | ABIO | ARCA biopharma, In ... | GAVIN JAMES R III | Director | Option Exercise | A | 3.67 | 15,000 | 55,050 | 15,000 | |
| Feb 02 2007 | ABIO | ARCA biopharma, In ... | LEVY MICHAEL D | Sr. VP Research & D ... | Option Exercise | A | 3.54 | 2 | 7 | 2 | |
| Feb 02 2007 | ABIO | ARCA biopharma, In ... | LEVY MICHAEL D | Sr. VP Research & D ... | Option Exercise | A | 3.54 | 129,998 | 460,193 | 129,998 | |
| Feb 02 2007 | ABIO | ARCA biopharma, In ... | LEVY MICHAEL D | Sr. VP Research & D ... | Buy | I | 16.32 | 42 | 685 | 4,680 | 4.6 K to 4.7 K (+0.91 %) |
| Feb 02 2007 | ABIO | ARCA biopharma, In ... | LEVY MICHAEL D | Sr. VP Research & D ... | Buy | I | 14.20 | 698 | 9,912 | 4,638 | 3.9 K to 4.6 K (+17.72 %) |
| Feb 02 2007 | ABIO | ARCA biopharma, In ... | LOVE TED W | C.E.O. | Option Exercise | A | 3.54 | 300,000 | 1,062,000 | 300,000 | |
| Feb 02 2007 | ABIO | ARCA biopharma, In ... | LOVE TED W | C.E.O. | Buy | I | 14.20 | 292 | 4,146 | 21,042 | 20.8 K to 21 K (+1.41 %) |
| Feb 02 2007 | ABIO | ARCA biopharma, In ... | Wolff Henry Ward | Sr. VP Finance and ... | Option Exercise | A | 3.54 | 12 | 42 | 12 | |
| Feb 02 2007 | ABIO | ARCA biopharma, In ... | Wolff Henry Ward | Sr. VP Finance and ... | Option Exercise | A | 3.54 | 99,988 | 353,958 | 99,988 | |
| Feb 02 2007 | ABIO | ARCA biopharma, In ... | Wolff Henry Ward | Sr. VP Finance and ... | Buy | I | 16.32 | 229 | 3,737 | 229 | 0 to 229 |
| Feb 02 2007 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr VP & General Cou ... | Option Exercise | A | 3.54 | 6 | 21 | 6 | |
| Feb 02 2007 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr VP & General Cou ... | Option Exercise | A | 3.54 | 99,994 | 353,979 | 99,994 | |
| Feb 02 2007 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr VP & General Cou ... | Buy | I | 16.32 | 164 | 2,676 | 1,248 | 1.1 K to 1.2 K (+15.13 %) |
| Feb 02 2007 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr VP & General Cou ... | Buy | I | 14.20 | 186 | 2,641 | 1,084 | 898 to 1.1 K (+20.71 %) |
| Nov 13 2006 | ABIO | ARCA biopharma, In ... | SOBEL BURTON E | Director | Option Exercise | M | 6.50 | 12,500 | 81,250 | 0 | |
| Nov 13 2006 | ABIO | ARCA biopharma, In ... | SOBEL BURTON E | Director | Sell | S | 18.17 | 12,500 | 227,136 | 0 | 12.5 K to 0 (-100.00 %) |
| Nov 13 2006 | ABIO | ARCA biopharma, In ... | SOBEL BURTON E | Director | Buy | M | 6.50 | 12,500 | 81,250 | 12,500 | 0 to 12.5 K |
| Oct 02 2006 | ABIO | ARCA biopharma, In ... | PERRY MARK L | Director | Buy | M | 14.66 | 15,000 | 219,900 | 65,833 | 50.8 K to 65.8 K (+29.51 %) |
| Oct 02 2006 | ABIO | ARCA biopharma, In ... | PERRY MARK L | Director | Buy | M | 6.73 | 15,000 | 100,875 | 50,833 | 35.8 K to 50.8 K (+41.86 %) |
| Oct 02 2006 | ABIO | ARCA biopharma, In ... | PERRY MARK L | Director | Buy | M | 6.50 | 25,000 | 162,500 | 35,833 | 10.8 K to 35.8 K (+230.78 %) |
| Oct 02 2006 | ABIO | ARCA biopharma, In ... | PERRY MARK L | Director | Buy | M | 11.11 | 7,500 | 83,318 | 10,833 | 3.3 K to 10.8 K (+225.02 %) |
| Oct 02 2006 | ABIO | ARCA biopharma, In ... | PERRY MARK L | Director | Buy | M | 9.12 | 3,333 | 30,397 | 3,333 | 0 to 3.3 K |
| Aug 31 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | Chief Acct.Officer | Sell | S | 20.70 | 14,000 | 289,800 | 2,633 | 16.6 K to 2.6 K (-84.17 %) |
| Aug 31 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | Chief Acct.Officer | Buy | M | 2.60 | 14,000 | 36,330 | 16,633 | 2.6 K to 16.6 K (+531.71 %) |
| Aug 30 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | Chief Acct.Officer | Sell | S | 20.65 | 6,831 | 141,060 | 2,633 | 9.5 K to 2.6 K (-72.18 %) |
| Aug 30 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | Chief Acct.Officer | Buy | M | 9.17 | 6,831 | 62,606 | 9,464 | 2.6 K to 9.5 K (+259.44 %) |
| Aug 28 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | Chief Acct.Officer | Sell | S | 19.88 | 20,000 | 397,602 | 2,633 | 22.6 K to 2.6 K (-88.37 %) |
| Aug 28 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | Chief Acct.Officer | Buy | M | 9.17 | 20,000 | 183,300 | 22,633 | 2.6 K to 22.6 K (+759.59 %) |
| Aug 28 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | Chief Acct.Officer | Sell | S | 20.00 | 10,000 | 199,950 | 2,633 | 12.6 K to 2.6 K (-79.16 %) |
| Aug 28 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | Chief Acct.Officer | Buy | M | 9.67 | 10,000 | 96,700 | 12,633 | 2.6 K to 12.6 K (+379.79 %) |
| Aug 28 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | Chief Acct.Officer | Sell | S | 20.00 | 10,000 | 199,950 | 2,633 | 12.6 K to 2.6 K (-79.16 %) |
| Aug 28 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | Chief Acct.Officer | Buy | M | 9.21 | 10,000 | 92,100 | 12,633 | 2.6 K to 12.6 K (+379.79 %) |
| Aug 25 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | Chief Acct.Officer | Sell | S | 19.50 | 15,000 | 292,500 | 2,633 | 17.6 K to 2.6 K (-85.07 %) |
| Aug 25 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | Chief Acct.Officer | Buy | M | 9.83 | 15,000 | 147,375 | 17,633 | 2.6 K to 17.6 K (+569.69 %) |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | VP Finance, Chief A ... | Option Exercise | A | 16.74 | 25,000 | 418,500 | 25,000 | |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | VP Finance, Chief A ... | Option Exercise | A | 16.74 | 5,000 | 83,700 | 5,000 | |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | VP Finance, Chief A ... | Buy | I | 13.90 | 90 | 1,251 | 2,633 | 2.5 K to 2.6 K (+3.54 %) |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | VP Finance, Chief A ... | Buy | I | 7.38 | 169 | 1,247 | 1,543 | 1.4 K to 1.5 K (+12.30 %) |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | VP Finance, Chief A ... | Buy | I | 7.40 | 169 | 1,251 | 1,374 | 1.2 K to 1.4 K (+14.02 %) |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | Titus Gary | VP Finance, Chief A ... | Buy | I | 6.33 | 176 | 1,114 | 1,205 | 1 K to 1.2 K (+17.10 %) |
| Aug 14 2006 | ABIO | ARCA biopharma, In ... | SOBEL BURTON E | Director | Sell | S | 16.00 | 12,500 | 200,000 | 0 | 12.5 K to 0 (-100.00 %) |
| Aug 14 2006 | ABIO | ARCA biopharma, In ... | SOBEL BURTON E | Director | Buy | M | 6.50 | 12,500 | 81,250 | 12,500 | 0 to 12.5 K |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | LOVE TED W | C.E.O. | Option Exercise | A | 16.74 | 3,040 | 50,890 | 3,040 | |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | LOVE TED W | C.E.O. | Option Exercise | A | 16.74 | 371,960 | 6,226,610 | 371,960 | |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | LOVE TED W | C.E.O. | Buy | I | 13.90 | 1,132 | 15,735 | 4,423 | 3.3 K to 4.4 K (+34.40 %) |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | LOVE TED W | C.E.O. | Buy | I | 6.33 | 913 | 5,779 | 3,291 | 2.4 K to 3.3 K (+38.39 %) |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | LEVY MICHAEL D | Sr. VP Research & D ... | Option Exercise | A | 16.74 | 5,975 | 100,022 | 5,975 | |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | LEVY MICHAEL D | Sr. VP Research & D ... | Option Exercise | A | 16.74 | 74,025 | 1,239,179 | 74,025 | |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | LEVY MICHAEL D | Sr. VP Research & D ... | Buy | I | 13.90 | 701 | 9,744 | 3,687 | 3 K to 3.7 K (+23.48 %) |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | LEVY MICHAEL D | Sr. VP Research & D ... | Buy | I | 6.33 | 1,500 | 9,495 | 2,986 | 1.5 K to 3 K (+100.94 %) |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr VP & General Cou ... | Option Exercise | A | 16.74 | 5,486 | 91,836 | 5,486 | |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr VP & General Cou ... | Option Exercise | A | 16.74 | 44,514 | 745,164 | 44,514 | |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr VP & General Cou ... | Buy | I | 13.90 | 189 | 2,627 | 898 | 709 to 898 (+26.66 %) |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr VP & General Cou ... | Buy | I | 7.38 | 355 | 2,620 | 709 | 354 to 709 (+100.28 %) |
| Aug 02 2006 | ABIO | ARCA biopharma, In ... | BENDEKGEY E LEE | Sr VP & General Cou ... | Buy | I | 7.40 | 354 | 2,620 | 354 | 0 to 354 |
| Jul 24 2006 | ABIO | ARCA biopharma, In ... | Wolff Henry Ward | Sr. VP Finance and ... | Option Exercise | A | 17.03 | 23,492 | 400,069 | 23,492 | |
| Jul 24 2006 | ABIO | ARCA biopharma, In ... | Wolff Henry Ward | Sr. VP Finance and ... | Option Exercise | A | 17.03 | 151,508 | 2,580,181 | 151,508 | |
| Jun 09 2006 | ABIO | ARCA biopharma, In ... | SOBEL BURTON E | Director | Sell | S | 15.59 | 7,500 | 116,903 | 52,500 | 60 K to 52.5 K (-12.50 %) |